Recent News

• 05.28.2025 - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
• 05.08.2025 - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
• 05.05.2025 - TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
• 05.02.2025 - TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
• 05.01.2025 - TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
• 04.21.2025 - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Recent Filings

• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - 8-K Current report
• 05.05.2025 - 8-K Current report
• 05.05.2025 - EX-99.1 EX-99.1
• 05.02.2025 - EX-99.1 EX-99.1
• 05.02.2025 - 8-K Current report
• 04.30.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.21.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.21.2025 - 8-K Current report
• 04.21.2025 - EX-99.1 EX-99.1